human frp2 receptor inhibitor boc mlf  (MedChemExpress)

Journal: iScience

Article Title: Annexin A1 exerts analgesic effect in a mouse model of medication overuse headache

doi: 10.1016/j.isci.2023.108153

Figure Lengend Snippet:

Article Snippet: Boc-MLF TFA , MedChemExpress , CatHY-103473A.

Techniques: Recombinant, SYBR Green Assay, Lysis, Protease Inhibitor, Bicinchoninic Acid Protein Assay, Western Blot, Software, Microscopy, Real-time Polymerase Chain Reaction, Imaging, Injection

Journal: iScience

Article Title: Annexin A1 exerts analgesic effect in a mouse model of medication overuse headache

doi: 10.1016/j.isci.2023.108153

Figure Lengend Snippet:

Article Snippet: The stock solutions of the formyl peptide receptor (FPR) antagonist Boc-MLF TFA (MedChemExpress LLC, HY-103473A, Shanghai, China) were prepared by dissolving it in dimethyl sulfoxide.

Techniques: Recombinant, SYBR Green Assay, Lysis, Protease Inhibitor, Bicinchoninic Acid Protein Assay, Western Blot, Software, Microscopy, Real-time Polymerase Chain Reaction, Imaging, Injection

Journal: iScience

Article Title: Annexin A1 exerts analgesic effect in a mouse model of medication overuse headache

doi: 10.1016/j.isci.2023.108153

Figure Lengend Snippet:

Article Snippet: Boc-MLF TFA , MedChemExpress , Cat#HY-103473A.

Techniques: Recombinant, SYBR Green Assay, Lysis, Protease Inhibitor, Bicinchoninic Acid Protein Assay, Western Blot, Software, Microscopy, Real-time Polymerase Chain Reaction, Imaging, Injection

Journal: Frontiers in Pharmacology

Article Title: The Role of Formyl Peptide Receptor 1 in Uterine Contraction During Parturition

doi: 10.3389/fphar.2021.696697

Figure Lengend Snippet: FPR1 expression in human laboring myometrium. (A,B) RT-qPCR and western blotting of the expression level of FPR1 in TL myometrium compared to TNL myometrium. * p < 0.05, **** p < 0.0001. (C) Frozen sections of TL myometrial tissues were stained by immunofluorescence for the expression of FPR1 (Alex Fluor ® 488, green) and MPO (Cy3, red), as described in Materials and Methods. Cell nuclei were stained with DAPI (blue). Images shown are representative of three independent experiments with similar results. Scale bar, 10 µm. (D) Immunofluorescence for the expression of FPR1 (green), co-labeled with DAPI (blue) in HutSMCs (human uterine smooth muscle cells). Scale bar, 40 µm. (E) The expression of FPR1 in HutSMCs with K-562 cell line as positive control by WB assay.

Article Snippet: N-Formyl-Met-Leu-Phe (fMLF, agonist of FPR1, MCE, United States) and Boc-MLF TFA (tBOC, antagonist of FPR1, MCE, United States) were dissolved in dimethyl sulfoxide (DMSO, Sigma, United States) to a final concentration of less than 0.1%.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Staining, Immunofluorescence, Labeling, Positive Control

Journal: Frontiers in Pharmacology

Article Title: The Role of Formyl Peptide Receptor 1 in Uterine Contraction During Parturition

doi: 10.3389/fphar.2021.696697

Figure Lengend Snippet: FPR1 activation promotes HutSMC contraction. (A) The effect of FPR1 on spontaneous contraction in HutSMCs treated with DMSO (control), tBOC (5 μM), fMLF (10 μM), or fMLF/tBOC combination for 24 h, which was determined by gel areas. (B) The effect of FPR1 on oxytocin-induced contraction in HutSMCs treated with DMSO (control), tBOC (5 μM), fMLF (10 μM), or fMLF/tBOC combination for 24 h, which was determined by intracellular calcium concentration. The concentration was reflected by fluorescence intensity. * p < 0.05 compared with control, # p < 0.05 compared with fMLF group.

Article Snippet: N-Formyl-Met-Leu-Phe (fMLF, agonist of FPR1, MCE, United States) and Boc-MLF TFA (tBOC, antagonist of FPR1, MCE, United States) were dissolved in dimethyl sulfoxide (DMSO, Sigma, United States) to a final concentration of less than 0.1%.

Techniques: Activation Assay, Control, Concentration Assay, Fluorescence

Journal: Frontiers in Pharmacology

Article Title: The Role of Formyl Peptide Receptor 1 in Uterine Contraction During Parturition

doi: 10.3389/fphar.2021.696697

Figure Lengend Snippet: FPR1 activation promoted expression of contractile proteins and MAPKs phosphorylation. (A) The protein expression of contractile proteinss in HutSMCs treated with DMSO (control), tBOC (5 μM), fMLF (10 μM), or fMLF/tBOC combination. (B) Distribution and expression of MLC phosphorylation in HutSMCs. Scale Bar = 40 μm. (C) The effect of FPR1 on MAPKs phosphorylation in HutSMCs treated with DMSO (control), tBOC (5 μM), fMLF (10 μM), or fMLF/tBOC combination for 24 h * p < 0.05 compared with control, # p < 0.05 compared with fMLF group.

Article Snippet: N-Formyl-Met-Leu-Phe (fMLF, agonist of FPR1, MCE, United States) and Boc-MLF TFA (tBOC, antagonist of FPR1, MCE, United States) were dissolved in dimethyl sulfoxide (DMSO, Sigma, United States) to a final concentration of less than 0.1%.

Techniques: Activation Assay, Expressing, Control

Journal: Frontiers in Pharmacology

Article Title: The Role of Formyl Peptide Receptor 1 in Uterine Contraction During Parturition

doi: 10.3389/fphar.2021.696697

Figure Lengend Snippet: Scheme demonstrating the possible underlying mechanisms of FPR1 activation in myometrial contraction. Abbreviations: CAPs, contraction-associated proteins; Cx43, connexin 43; MLCK, myosin light chain kinase; pMLC, phosphorylated myosin light chain; OXTR, oxytocin receptor; SR, sarcoplasmic reticulum.

Article Snippet: N-Formyl-Met-Leu-Phe (fMLF, agonist of FPR1, MCE, United States) and Boc-MLF TFA (tBOC, antagonist of FPR1, MCE, United States) were dissolved in dimethyl sulfoxide (DMSO, Sigma, United States) to a final concentration of less than 0.1%.

Techniques: Activation Assay